Traders sold shares of Edwards Lifesciences Corp (NYSE:EW) on strength during trading on Thursday following insider selling activity. $39.64 million flowed into the stock on the tick-up and $55.03 million flowed out of the stock on the tick-down, for a money net flow of $15.39 million out of the stock. Of all companies tracked, Edwards Lifesciences Corp had the 28th highest net out-flow for the day. Edwards Lifesciences Corp traded up $1.82 for the day and closed at $86.86Specifically, VP Donald E. Bobo, Jr. sold 18,000 shares of Edwards Lifesciences Corp stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $115.78, for a total value of $2,084,040.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $92.77, for a total value of $4,555,007.00. The disclosure for this sale can be found here. 2.37% of the stock is owned by company insiders.

EW has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price objective on Edwards Lifesciences Corp from $110.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 27th. Zacks Investment Research upgraded Edwards Lifesciences Corp from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 16th. JMP Securities lifted their price objective on Edwards Lifesciences Corp from $125.00 to $130.00 and gave the stock a “market outperform” rating in a research note on Thursday, July 28th. Canaccord Genuity reiterated a “buy” rating and issued a $140.00 price objective on shares of Edwards Lifesciences Corp in a research note on Thursday, August 18th. Finally, Royal Bank Of Canada lowered their price target on Edwards Lifesciences Corp from $130.00 to $123.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $117.68.

The company’s 50 day moving average price is $102.00 and its 200-day moving average price is $106.84. The stock has a market capitalization of $18.57 billion, a price-to-earnings ratio of 34.33 and a beta of 0.71.

Edwards Lifesciences Corp (NYSE:EW) last issued its earnings results on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.68. Edwards Lifesciences Corp had a net margin of 19.24% and a return on equity of 24.32%. The firm had revenue of $739.40 million for the quarter, compared to analyst estimates of $749.14 million. During the same quarter last year, the business posted $0.54 earnings per share. The company’s quarterly revenue was up 20.1% on a year-over-year basis. On average, equities analysts expect that Edwards Lifesciences Corp will post $2.88 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of EW. HighPoint Advisor Group LLC raised its stake in shares of Edwards Lifesciences Corp by 17.9% in the third quarter. HighPoint Advisor Group LLC now owns 2,324 shares of the medical research company’s stock worth $211,000 after buying an additional 353 shares in the last quarter. ETRADE Capital Management LLC raised its stake in shares of Edwards Lifesciences Corp by 10.4% in the third quarter. ETRADE Capital Management LLC now owns 3,720 shares of the medical research company’s stock worth $449,000 after buying an additional 349 shares in the last quarter. D.A. Davidson & CO. raised its stake in shares of Edwards Lifesciences Corp by 1,722.8% in the third quarter. D.A. Davidson & CO. now owns 5,833 shares of the medical research company’s stock worth $703,000 after buying an additional 5,513 shares in the last quarter. Scout Investments Inc. raised its stake in shares of Edwards Lifesciences Corp by 41.5% in the third quarter. Scout Investments Inc. now owns 366,967 shares of the medical research company’s stock worth $44,242,000 after buying an additional 107,647 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC raised its stake in shares of Edwards Lifesciences Corp by 63.6% in the third quarter. Quantitative Systematic Strategies LLC now owns 13,941 shares of the medical research company’s stock worth $1,664,000 after buying an additional 5,418 shares in the last quarter. Hedge funds and other institutional investors own 83.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/24/investors-sell-edwards-lifesciences-corp-ew-on-strength-after-insider-selling.html.

Edwards Lifesciences Corp Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Receive News & Stock Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related stocks with our FREE daily email newsletter.